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Abstract
Introduction: Schistosomiasis (bilharzia), one of the most relevant parasitoses of humans, is confirmed by microscopic
detection of eggs in stool, urine, or organ biopsies. The sensitivity of these procedures is variable due to fluctuation of egg
shedding. Serological tests on the other hand do not distinguish between active and past disease. In patients with acute
disease (Katayama syndrome), both serology and direct detection may produce false negative results. To overcome these
obstacles, we developed a novel diagnostic strategy, following the rationale that Schistosoma DNA may be liberated as a
result of parasite turnover and reach the blood. Cell-free parasite DNA (CFPD) was detected in plasma by PCR.
Methodology/Principal Findings: Real-time PCR with internal control was developed and optimized for detection of CFPD
in human plasma. Distribution was studied in a mouse model for Schistosoma replication and elimination, as well as in
human patients seen before and after treatment. CFPD was detectable in mouse plasma, and its concentration correlated
with the course of anti-Schistosoma treatment. Humans with chronic disease and eggs in stool or urine (n=14) showed a
100% rate of CFPD detection. CFPD was also detected in all (n=8) patients with Katayama syndrome. Patients in whom no
viable eggs could be detected and who had been treated for schistomiasis in the past (n=30) showed lower detection rates
(33.3%) and significantly lower CFPD concentrations. The duration from treatment to total elimination of CFPD from plasma
was projected to exceed one year.
Conclusions/Significance: PCR for detection of CFPD in human plasma may provide a new laboratory tool for diagnosing
schistosomiasis in all phases of clinical disease, including the capacity to rule out Katayama syndrome and active disease.
Further studies are needed to confirm the clinical usefulness of CFPD quantification in therapy monitoring.
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Introduction
Schistosomiasis, also known as bilharzia, is caused by trema-
todes of the Schistosomatidae family. It is among the most important
parasitic diseases worldwide, with a significant socio-economic
impact [1]. More than 200 million people are infected, and about
200,000 may die from the disease each year. On a global scale,
one of thirty individuals has schistosomiasis [2]. Movements of
refugees, displacement of people, and mistakes in freshwater
management promote the spread of schistosomiasis [3,4].
Human disease is caused by S. haematobium, S. mansoni, S.
japonicum, and less frequently, S. mekongi and S. intercalatum [5,6].
Infection with cercariae occurs through intact skin via contact with
infested water. Penetration of cercariae is followed by Katayama
syndrome, an acute syndrome with fever, rash and eosinophilia.
The syndrome is thought to be caused by antigen excess due to the
presence of schistosomules in blood and the beginning of egg
deposition [5,6]. After maturation in the lung and liver sinusoids,
adult male and female worms mate and actively migrate to their
target organs [4,5]. S. haematobium resides in walls of the bladder
and sacral and pelvic blood vessels surrounding the urinary tract.
The other mentioned species reside in mesenteric veins. After
deposition of eggs in the capillary system, eggs penetrate the
mucosa of target organs and are excreted in urine or feces.
Sequelae of acute and chronic infection include hepato-splenic
disease, portal hypertension with varices, pulmonary hypertension,
squamous cell cancer of the bladder, liver fibrosis, and less
common conditions such as myelo-radiculitis and female genital
schistosomiasis. Co-infections with HCV and Schistosoma may also
modify the course of hepatitis C [4,7–14].
Anti-Schistosoma antibodies can be detected by enzyme immu-
noassay (EIA), immunofluorescence assay (IFA), and indirect
hemagglutination assay [15]. Antibody detection is valuable in
patients with rare exposure to Schistosoma, e.g., tourists. In patients
with Katayama syndrome, a positive EIA antibody test is usually
the earliest diagnostic laboratory result. Still, a large fraction of
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prevent timely treatment of schistosomiasis in travellers who
present with fever of unknown origin. Moreover, the inability of
serology to discriminate between active and past disease limits its
clinical value for confirmation of the success of treatment [18].
Microscopic demonstration of eggs in stool or urine specimens is
considered the diagnostic gold standard for confirmation of
schistosomiasis in patients from endemic countries, as well as for
the confirmation of the success of treatment. In field studies the
rapid and inexpensive Katz-Kato thick smear technique is often
used [19]. Because the shedding of eggs is highly variable, it is
necessary to concentrate eggs from stool or urine prior to
examination [20]. Even in concentrated samples the sample
volume analysed in the microscope is limited. Due to random
distribution effects, the analysed sample may not contain eggs even
if the disease is active. It is thus very difficult to achieve a
conclusive confirmation of successful therapy. In symptomatic
patients with unsuccessful egg detection, it is often necessary to
perform endoscopic biopsies of the bladder or rectal mucosa to
increase the chance of detection [20].
Several groups have developed polymerase chain reaction
(PCR) methods to improve the direct detection of Schistosoma.
These tests are done on urine, stool, or organ biopsy samples, and
involve the preparation of DNA from eggs prior to PCR
amplification [21,22]. Unfortunately, only a small volume of
sample can be processed for DNA extraction, and it is dependent
on chance whether the processed sample contains eggs or not. In
this regard, PCR has the same limitations as microscopy and does
not provide a significant clinical benefit.
The detection of circulating cell-free DNA in human plasma has
long been explored for the non-invasive diagnosis of a variety of
clinical conditions (reviewed in [23] and [24]). It has been known
since almost 20 years that patients with solid tumors have tumor-
derived DNA circulating in plasma that can be used for diagnostic
purposes [25–28]. Circulating fetal DNA in maternal plasma is
used for diagnosing and monitoring of a range of fetal diseases and
pregnancy-associated complications [29–33]. The normal concen-
tration of cell-free DNA in plasma of adults is 10–100 ng/mL or
10e3 to 10e4 human genome equivalents per mL [34,35]. It has
been determined that the concentration of fetal DNA in maternal
plasma is 3.4% of total serum DNA on average [16]. The presence
of cell-free DNA in plasma may be a consequence of apoptosis,
which is associated with physiological and pathological turnover of
tissue, e.g., in tumor growth or embryonic development (reviewed
in [36] and references therein).
In parasitic diseases such as schistosomiasis, there is a huge
turnover of parasites involving replication, maturation, and death
of organisms. Multi-cellular parasites like Schistosoma contain DNA
copies in stoichiometrical excess over parasite count. We reasoned
that it might be possible to find cell-free parasite DNA (CFPD)
circulating in plasma, and that this could be used to diagnose
schistosomiasis. In contrast to eggs in stool or urine, CFPD would
be equally distributed throughout the plasma volume of the
patient, resolving the issue of random sampling that spoils clinical
sensitivity of classical detection methods. As an extension of this
rationale, we reasoned that it might also be possible to confirm the
elimination of Schistosoma CFPD after successful treatment. To
prove these concepts, Schistosoma-specific real-time PCR was
established and optimised for detection of DNA from large
volumes of plasma. A Balb/c mouse model of schistosomiasis was
used to study the levels of CFPD in plasma during infection, as
well as during and after therapy. The concept was then transferred
to patients with different stages of infection, including Katayama
syndrome, chronic disease with egg excretion, and patients treated
for schistosomiasis in the past without current signs of disease.
Materials and Methods
Ethics statement
Written informed consent was obtained from every patient. The
study was approved by the ethics committee of the Board of
Physicians of the City of Hamburg.
Animal model of S. mansoni infection
The Liberian isolate of S. mansoni [37], was maintained in
Biomphalaria glabrata and Syrian hamsters. Maintenance of the life
cycle was exactly performed as described elsewhere [38]. Adult
female Balb/c mice (Charles Rivers Laboratories, Sulzfelden,
Germany) were infected by intraperitoneal injection of 100
cercariae diluted in 200 mL sterile isotonic saline solution.
Approval was obtained from the animal protection board of the
City of Hamburg.
Patients
The study included patients with Katayama syndrome (n=8)
defined by fever, eosinophilia and a history of surface freshwater
contact during a recent travel to a schistosomiasis endemic region.
A second group had active, untreated disease defined by detection
of eggs in stool or urine (n=14). Most patients in this group were
immigrants from endemic regions presenting to their primary care
physician with acute manifestations like hematuria. Most of them
where not aware of their disease. A third group of patients had
treated schistosomiasis defined by prior anti-parasitic treatment
and failure to detect viable eggs by microscopy (n=30).
Samples
Serum and plasma samples were collected for antibody testing
and DNA extraction, respectively. Serum was stored at +4uC and
plasma was stored at 220uC prior to use. Stool samples were
Author Summary
Bilharzia (schistosomiasis) occurs in the tropics and
subtropics and is one of the most important parasite
diseases of humans. It is caused by flukes residing in the
vessels of the gut or bladder, causing fever, pain, and
bleeding. Bladder cancer or esophageal varices may follow.
Diagnosis is difficult, requiring detection of parasite eggs
in stool, urine, or gut/bladder biopsies. In this paper, we
introduce a fundamentally new way of diagnosing
bilharzia from the blood. It has been known for almost
20 years that patients with cancer have tumor-derived
DNA circulating in their blood, which can be used for
diagnostic purposes. During pregnancy, free DNA from the
fetus can be detected in motherly blood, which can be
used for diagnosing a range of fetal diseases and
pregnancy-associated complications. We found that para-
site DNA can be detected in the same way in the blood of
patients with bilharzia. In patients with early disease,
diagnosis was possible earlier than with any other test.
DNA could be detected in all patients with active disease
in our study. Patients after treatment had significantly
lower parasite DNA concentrations and turned negative 1–
2 years after treatment. Future studies should implement
the method in large cohorts of patients and should define
criteria for the confirmation of the success of treatment by
comparing the concentration of fluke DNA before and
after therapy.
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until use.
Serology
All patient sera were tested for anti-Schistosoma antibodies by
means of an extensively validated in-house EIA that has been
described previously [15]. EIA used crude extracts from cercariae
and adult worms of S. haematobium and S. mansoni, as well as extracts
from adult worms of S. japonicum.
Parasite detection
Stool investigation was done essentially as described earlier [15].
For detection of S. haematobium eggs, urine was filtered as described
by Peters et al. [39]. Microscopy was performed directly on
untreated biopsies and on paraffin-embedded tissue. The latter
was cut with a microtome into 5-mm sections. The sections were
subsequently mounted on glass slides, stained with hematoxylin-
eosin, periodic acid–Schiff and Trichrome stains and subsequently
examined by an experienced pathologist for Schistosoma eggs.
Plasma DNA preparation
DNA from plasma was prepared by large volume phenol-
chloroform extraction. In brief, up to 20 mL of plasma were
mixed with an equal volume of phenol and centrifuged for 5 min
at 1,200 g. The aqueous phase was transferred to a new tube,
mixed with an equal volume of phenol:chloroform 1:1, and
centrifuged 5 min at 3,500 rpm. Again the aqueous phase was
transferred to a new tube, mixed with an equal volume of
chloroform, and centrifuged 5 min at 3,500 rpm. DNA was
precipitated by adding 1/10 volume of 3 M sodium acetate and 1
volume of 99% ethanol. After centrifugation for 1 h at 14,000 g
the supernatant was discarded. To remove residual salt the pellet
was washed with 1 mL ethanol 70% and centrifuged 20 min at
10,000 rpm. Supernatant was discharged. The DNA pellet was
air-dried and dissolved in 50 mL of water and stored at 220uC.
Real-time PCR
In order to achieve high analytical sensitivity, the 121 bp tandem
repeat sequence (GenBank accession number M61098) that
contributes about 12% of the total Schistosoma mansoni genome
sequence was chosen as the PCR target gene [40]. 20 mLr e a c t i o n s
contained 3 mLo fD N A ,2mL 10X Platinum Taq PCR-Buffer
(Invitrogen, Karlsruhe, Germany), 1.5 mLM g C l 2 (50 mM), 200 mM
of each dNTP, 0.8 mg bovine serum albumin, 500 nM of primers
SRA1 (CCACGCTCTCGCAAATAATCT and SRS2 (CAACCG-
TTCTATGAAAATCGTTGT) each, 300 nM of probe SRP (FAM-
TCCGAAACCACTGGACGGATTTTTATGAT-TAMRA), and
1.25 units of Platinum Taq polymerase (Invitrogen). Cycling in a
Roche LightCyclerHversion 1.2 comprised: 95uC/5 min,45cyclesof
58uC/30 s and 95uC/10 s. Fluorescence was measured once per
cycle at the end of the 58uCs e g m e n t .
Quantification standard and technical sensitivity
The PCR target fragment was cloned into plasmid by means of
a pCR 2.1-TOPO TA cloning reagent set (Invitrogen, Carlsbad,
California, USA). Plasmid purification was done with a QIAprep
MiniPrep kit (Qiagen, Hilden, Germany). Plasmids were quanti-
fied by spectrophotometry. The standard plasmid was tested in 10-
fold dilution series by PCR, showing a detection limit of 5.4 copies
per reaction. If plasmids were inoculated into 200 mL of plasma
prior to preparation, 68.8 copies per mL of plasma were
detectable. Because the DNA contained in 200 mL was concen-
trated in 50 mL elution volume, of which 3 mL were tested by
PCR, the PCR input at 68.8 copies per mL corresponded to a
calculated 0.8 copies per PCR. Dilutions of the standard plasmid
were also used as a quantification reference in real-time PCR. It
should be mentioned that only approximate concentrations of
Schistosoma DNA can be determined because the number of copies
per genome of our target sequence varies between S.mansoni and
hematobium and is unknown for S. japonicum [40].
Internal control
Target gene nucleotides 39–79 bp were removed from the
quantification standard plasmid, and replaced by an alternative
probe binding site with techniques described earlier [41], using
primers SRA-mut (ATCGTTCGTTGAGCGATTAGCAGTTT
GTTT TAGATTATTTGCGGAGCGTGG) and SRS2-mut
(CTGCTAATCGCTCAACGAAC GATTACAACGATTTT-
CATAGAACGGTTGG) for extension PCR, in combination
with diagnostic PCR primers mentioned above. The resulting
construct was cloned as described in the section ‘‘quantification
standard’’.
Optimization of Schistosoma PCR for large plasma
volumes
One whole schistosome was ground in liquid nitrogen. Its
nucleic acids were extracted and inoculated into human normal
plasma. Different volumes of plasma were prepared by classical
phenol-chloroform extraction, keeping the water volume in which
DNA was resuspended at the end of the procedure constant at
50 mL. Parallel PCRs conducted on these nucleic acid solutions
showed that an increase of detection signal was achieved up to an
input volume of 10 mL of plasma, as evident by reduction of Ct
values in real-time PCR. Above this input volume, no increase of
signal was observed anymore, probably due to the introduction of
interfering substances into PCR that were derived from large
volumes of plasma. These experiments were repeated and
confirmed with plasmid DNA spiked in human plasma. An input
volume in humans of 10 mL of plasma was chosen as the volume
to be analyzed in human diagnostic application in this study. It
should be mentioned that outside this study, smaller volumes of
plasma (down to 1 mL) were successfully used for CFPD detection.
Quantitative correction factors
Different input volumes of plasma were processed for mice or
humans, respectively. For mice, 1 mL of plasma was extracted and
the resultingDNAresuspendedin 50 mL, of which3 mL were tested
in PCR. One DNA copy per PCR vial thus represented 16.7 copies
per mL (50 / 3). For Humans, 10 mL of plasma were extracted and
resuspended in 50 mL of water, of which 3 mL were tested in PCR.
One DNA copy per PCR vial thus represented 1.67 copies per mL.
Confirmation of PCR specificity
Plasma from 30 blood donors and 35 patients examined for
other conditions were tested by large-volume plasma extraction
and CFPD real-time PCR. None yielded positive results.
Statistical analysis
The Statgraphics V 5.1 software package (Manugistics,
Dresden, Germany) was use for all statistical analyses. T-tests
were always two-tailed.
Results
In the case of tumors and pregnancy, cell-free DNA can be
detected in plasma. Because the high turn-over rates of cells in
Schistosomiasis Plasma PCR
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tions, we reasoned that the detection of cell-free DNA from
infecting parasites (CFPD) might be effective as a diagnostic
approach in schistosomiasis. In preliminary experiments, stored
serum samples from humans with confirmed schistosomiasis were
processed with a method commonly used for detection of DNA
viruses from cell-free plasma [42] and tested by Schistosoma PCR
[21]. Plasma samples from mice infected with S. mansoni were also
tested. In both cases, Schistosoma DNA was detectable in some but
not all of the tested samples (data not shown).
To determine systematically under which conditions and at
what quantities CFPD was detectable in schistosomiasis, a
quantitative real-time PCR assay for a Schistosoma multi-copy gene
was established as described in the Materials and Methods section.
A well-established mouse model of schistosomiasis was employed.
In a first step it was tested whether CFPD circulated in plasma
during the phase of chronic schistosomiasis. Four adult BALB/c
mice were infected with 100 cercariae of S. mansoni and sacrificed
after completion of the replication cycle on day 42 after infection.
To enable testing of a large volume of mouse plasma, blood was
pooled from four mice and one mL of pooled plasma was
extracted. Quantitiative PCR with an absolute quantification
standard (refer to Materials and Methods section) yielded a DNA
concentration of 128.27 copies of CFPD target gene per mL of
plasma (Figure 1, marked datum point).
It was next determined whether any associations might exist
between the amount of living parasites in mice and the
concentration of CFPD. Along with the four mice mentioned
above, 16 more mice had been infected on the same day with the
same dose of S. mansoni cercariae. On day 45 post infection all 16
mice were treated with a single oral dose of 120 mg praziquantel
per gram body weight. This dose was known to eliminate
Schistosoma in our model (own unpublished data). Groups of four
mice were sacrificed on days 50, 80, 120, and 180 after infection,
respectively, and from each group one mL of pooled plasma was
tested. Figure 1 summarizes the CFPD target gene concentrations
observed in all groups of mice, including the untreated group.
Interestingly, in mice sacrificed five days after treatment the
Schistosoma CFPD concentration in pooled plasma was consider-
ably increased against the group that was sacrificed immediately
before treatment (899.23 vs 128.27 target gene copies per mL).
CFPD concentrations decreased to 182.93 and 70.97 target gene
copies/mL on days 80 and 120, respectively, and became
undetectable in the last group sampled on day 135 post treatment.
It was concluded that the concentration of CFPD in plasma might
be associated with the number of viable parasites or eggs in the
mouse model, and the observed increase of CFPD immediately
after treatment may have been due to parasite decay.
To determine whether CFPD could also be detected in humans,
fourteen patients with chronic disease were studied. These patients
Figure 1. DNA copies per mL of pooled mouse plasma (y-axis,
four mice per datum point) in mice infected intraperitoneally
with 100 cercariae of S. mansoni. After completion of parasite
maturation on day 42, mice were treated orally with praziquantel on
day 45 (120 mg per kg). At the indicated times (x-axis), four mice were
sacrificed, their blood pooled, and 1 mL of pooled plasma was tested as
described in the Materials and Methods section for cell-free Schistosoma
DNA. The untreated group is marked with an asterisk (*).
doi:10.1371/journal.pntd.0000422.g001
Table 1. Patients with chronic disease.
Patient
Suspected origin
of infection
Country of
residence
Residence
status EIA
Schistosoma
species
Sample in which
eggs were detected
Cell-free DNA
cop/mL
a
1 West Africa No data available Refugee + S. haematobium Bladder biopsy 27930.64
2 Mozambique Germany NGO worker + S. mansoni Rectum biopsy 27930.64
3 Nigeria Nigeria Immigrant + S. mansoni Rectum biopsy 3247.14
4 Egypt Egypt Immigrant + S. mansoni Rectum biopsy 1584.80
5 Egypt Egypt Immigrant + S. mansoni Rectum biopsy 1584.80
6 Philippines Germany Expatriate + S. japonicum Rectum biopsy 1584.80
7 Egypt Egypt Immigrant + S. mansoni Rectum biopsy 773.48
8 Zambia Germany NGO worker + S. mansoni Rectum biopsy 377.50
9 West Africa No data available Refugee + S. mansoni Rectum biopsy 184.24
10 Ghana Ghana Immigrant + S. mansoni Rectum biopsy 184.24
11 Gambia/Senegal Gambia/Senegal Immigrant + S. mansoni Rectum biopsy 21.42
12 West Africa West Africa Immigrant + S. haematobium Urine 21.42
13 Uganda Uganda Immigrant + S. mansoni Stool 2.49
14 Egypt Egypt Immigrant + S. mansoni Rectum biopsy 1.22
aNote that 10 mL of plasma were processed. 1 copy per mL=1.67 copies per PCR vial.
doi:10.1371/journal.pntd.0000422.t001
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identified in routine screening for gastrointestinal conditions or
other symptoms compatible with Schistosomiasis. It could not be
reconstructed how long these patients had been infected, or how
long ago they had been exposed. Diagnoses were initially made by
EIA. Active infections were subsequently confirmed in all patients
by microscopic detection of intact eggs in urine, stool, or organ
biopsies. Either S. mansoni,o rS. haematobium,o rS. japonicum eggs
were seen (Table 1). From each patient, 10 mL of plasma were
extracted and tested for Schistosoma CFPD. All patients tested
positive. The observed CFPD concentrations ranged from 1.22 to
27,930 target gene copies per mL of plasma.
Because of the high detection rates in patients with active
disease, it was tested whether CFPD might already be detectable
in the early acute disease (Katayama syndrome). Eight patients
were studied, as shown in Table 2. All of these patients had acute
disease that was confirmed subsequently to be associated with
Schistosoma infection. Although most patients were seen only in the
third week of symptoms, two patients could be tested already on
days 2 and 8 of symptoms, respectively. In three of eight patients,
antibody EIA was still negative during the first visit. CFPD PCR
was positive in all eight patients (Table 2). Target gene
concentrations in the cohort seemed to increase with increasing
times after exposure or after disease onset, as shown in Figure 2.
Highest values were observed about six weeks from exposure or
about 15 days from onset of symptoms.
It was next studied whether a decrease of CFPD concentration
due to treatment could be confirmed. In the group of patients with
Katayama syndrome, five of eight patients could be followed after
treatment (Table 2). All five patients received praziquantel and
prednisolon (1 mg/kg) within two weeks after initial diagnosis. A
second treatment course (same dose of praziquantel, no pre-
dnisolon) was conducted in all patients 4 to 6 weeks later. Patients
were appointed for control visits which took place 105 to 738 days
after the initial visit (rows labelled ‘‘second visit’’ in Table 2). As
expected, average leukocyte counts and levels of eosinophilia (%
eosinophiles in leukocyte count) were significantly lower in second
visits than in first visits. All patients had normal or only marginally
increased eosinophile levels during their second visits (Table 2).
Mean Schistosoma CFPD target gene concentrations in plasma were
17,040.20 copies/mL during first visits and 322.76 copies/mL
during second visits. Means were significantly different (two-tailed
T-test, p,0.05, Wilcoxon paired-sample test, p,0.04). Interest-
ingly, only one patient had a completely negative CFPD PCR test
during the second visit, and this was the patient with the longest
interval between treatment and second visit.
To obtain more data on Schistosoma CFPD concentrations after
treatment, we tested 30 patients who had been treated for
schistosomiasis during eight years in our institution, and who were
available for a re-visit. These patients were in good clinical
condition, had no eosinophilia, and had received between 1 and 6
treatment courses since their last exposure in endemic regions.
Patient histories are summarized in Table 3. Ten of the 30 patients
had positive CFPD PCR results. Intervals between treatment and
PCR testing were significantly different between PCR-positive and
PCR-negative patients (0.43 years vs. 3.4 years, p,0.0004,
ANOVA f-test). The longest interval between treatment and a
positive PCR result in any patient was 58 weeks. Interestingly,
three of the ten patients with positive PCR showed dead eggs in
histology.
To obtain an estimate of the approximate duration of CFPD
detection after therapy, the CFPD target gene concentrations were
plotted against time for all patients in this study who provided
positive PCR results after treatment (patients from the Katayama
syndrome ever group and post-treatment group). As shown in
Figure 3, linear regression or exponential curve fitting suggested
that negative results could be expected by weeks 82 or 120 after
treatment, respectively.
Table 2. Patients with Katayama syndrome.
Patient Destination Purpose Visit DPE
a DPO
b DPT
c LEUK
d EO
e EIA
f Cell-free DNA copies per mL
g
1 Mozambique Professional First 42 14 13.6 20.9 + 57227.85
Second 210 195 156 5.3 3.6 + 21.42
2 Ethiopia Professional First 42 15 10.2 26 2 27930.64
Second 135 120 79 7.3 4.1 + 1584.80
3 Uganda Professional First 56 18 10.1 19 + 21.42
Second 270 250 200 4.9 2.6 + 5.10
4 Uganda Professional First 12 20 7.3 22 + 10.45
Second 460 445 434 6.9 5.0 + 2.49
5 Malawi Tourist First 20 2 6.2 6.5 + 10.45
Second 750 740 716 5.2 0.8 + 2
6 Mozambique Tourist First 56 21 50.7 65 2 13631.84
7 Jemen Tourist First 54 14 6.7 23 + 773.48
8 Malawi Tourist First 35 8 4.9 19.7 2 184.24
aDays post exposure with fresh water (most likely event).
bDays post onset of symptoms.
cDays post treatment for second visits.
dLeukocyte count (n per nL). Average leukocyte count in patients 1 to 5: first visit, 9.48 cells/nl; second visit, 5.92 cells/nl (p,0.0017).
ePercent eosinophiles in total leukocytes. Average eosinophile fraction in patients 1 to 5: first visit, 18.88%; second visit: 3.2% (p,0.033).
fEnzyme immunoassay.
gNote that 10 mL of plasma were processed. 1 copy per mL=1.67 copies per PCR vial.
doi:10.1371/journal.pntd.0000422.t002
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Schistosomiasis involves a wide range of symptoms and is
difficult to diagnose. In this study we have explored the utility of
detecting cell-free parasite DNA (CFPD) in serum as an alternative
to detecting eggs in stool, urine, or organ biopsies. The concept of
using cell-free DNA for diagnostic purposes has been proven in
oncology and prenatal diagnostics [25–33]. It was our rationale
that schistosomiasis involves parasite turnover, liberating DNA
from decaying parasites that would reach the blood. Unlike eggs in
stool or urine, CFPD in plasma would not undergo random
sampling effects that complicate diagnostics.
By means of a well-established murine model of schistosomiasis,
it was confirmed that DNA could be detected in plasma during
active disease, and that praziquantel treatment led to clearance of
Schistosoma CFPD from plasma. Consistent with the hypothesis that
circulating Schistosoma DNA stemmed from decaying parasites, a
marked increase of CFPD concentration was observed in plasma
of mice sampled short after initiation of therapy.
Because of the large differences in plasma volume between mice
and humans, we have not undertaken any further mouse
experimentation but continued a proof-of-concept study on
available patients with schistosomiasis in various clinical stages.
In a first approach, we showed that CFPD could be detected in all
of 14 patients with active disease. Due to the small number of
available patients, this finding clearly awaits confirmation in larger
studies. It should also be mentioned that the sensitivity of our assay
may vary between Schistosoma species, as the target gene has not
been formally evaluated in S. japonicum (e.g., our whole study
contained only one patient with S. japonicum), and it has been
shown that S. hematobium contains less copies of it than S. mansoni
[40]. More recent PCR protocols (e.g., [21]) may be better suited
to detect all species with the same sensitivity. This study therefore
does clearly not provide a protocol intended for direct transfer into
clinical application. Nevertheless, it is an interesting perspective
that CFPD PCR might reach a clinical sensitivity of 100% for
active schistosomiasis. In industrialized countries, it may be easier
to find well-equipped molecular diagnostic laboratories than
experienced microscopists with sufficient expertise in Schistosoma
egg detection. Because of the ease of taking blood samples, and in
view of the risk contributed by undiagnosed Schistosomiasis, it
could become a realistic option to integrate Schistosoma CFPD PCR
in routine diagnostic regimens for the clarification of gastrointes-
tinal or urological conditions.
Katayama syndrome caused by acute Schistosoma infection is a
major differential diagnosis in returning travellers presenting with
fever of unknown origin [6]. Although eosinophilia is a helpful
criterion to distinguish Katayama syndrome from other conditions
such as malaria or dengue fever, it is difficult to make a distinctive
diagnosis due the shortcomings of serology and the inability of
demonstrating Schistosoma infection before egg production [14]. We
have demonstrated here that CFPD can be detected very early
after onset of symptoms in patients with Katayama syndrome.
Despite the limited number of patients studied, the concentrations
of CFPD observed in our patients were well above the detection
limit of the PCR assay. Based on experiments on limiting dilution
series and quantitative correction factors as described in the
Materials and Methods section, it could be assumed that the
technical sensitivity limit of our assay was ca. 1.67 CFPD target
gene copies per mL of plasma. The earliest patient with Katayama
syndrome sampled on day 2 of symptoms already had a plasma
concentration of ca. 10 copies per mL. If larger studies can
confirm the high clinical sensitivity seen in our study, the detection
of CFPD in plasma might become an accepted way of ruling out
Katayama syndrome. It should be mentioned here that we have
meanwhile modified our protocol by testing smaller volumes of
plasma (in the order of 1–2 mL) and using a larger input volume of
DNA in PCR. This modification makes the method easier to
handle in routine laboratories, and still seems to provide sufficient
sensitivity to diagnose patients with Katayama syndrome.
A third field of application is the monitoring of therapy. In order
to prevent relapse and long term sequelae from insufficient
treatment, it is important to achieve a laboratory confirmation of
the success of treatment [18,43–45]. Unfortunately, patients after
therapy as well as patients after a long course of disease with
spontaneous healing (‘‘burnt out bilharzia’’) are difficult to judge
based on clinical or laboratory findings [16,18]. Several repetitive,
parallel samplings are necessary to increase the statistical chance of
detection of eggs by microscope, and thus to increase the clinical
sensitivity of laboratory diagnostics [20,22,46]. This problem
applies not only to microscopy, but also to conventional PCR on
stool or urine samples [21,47]. In the latter tests, there are
additional issues such as PCR inhibition in stool samples. We have
shown here that the concentration of CFPD in plasma was
significantly reduced after therapy. The average CFPD concen-
tration in those patients who still had detectable DNA after
Figure 2. Cell-free Schistosoma DNA concentrations in plasma
of patients with acute disease (Katayama syndrome) plotted
against the days post exposure or post onset of symptoms
when the tested samples were taken. 10 mL of plasma were tested
for cell-free DNA.
doi:10.1371/journal.pntd.0000422.g002
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patients with Katayama syndrome (first visits, 537 copies per mL)
or active disease (323.6 copies per mL), as determined by ANOVA
(F-test, p,0.035; refer to Figure 4 for a Box Plot diagram). The
decline of CFPD concentration in patients before and after
treatment may thus become an effective parameter for monitoring
patients under therapy. On the contrary, we were surprised to see
that it took considerably longer in humans than in mice for CFPD
PCR to become entirely negative after treatment. Lo et al. have
determined that the half-life of fetal DNA in mother’s plasma after
birth ranges between 4 and 30 minutes [48]. In our study, pooled
data from patients followed prospectively and patients re-
examined retrospectively after treatment suggest that it may take
more than one year until CFPD becomes entirely undetectable.
Although we have no experimental evidence, it can be speculated
that inactive eggs may release DNA with very slow kinetics. The
greater number of eggs in humans with chronic disease as opposed
to mice in our experiments may be responsible for a considerably
longer duration until CFPD is totally eliminated in humans.
Future studies should address the utility of paired CFPD
determinations in individual patients before and after treatment,
rather than insisting on negative CFPD results for a confirmation
of treatment success.
In summary, the detection and quantification of CFPD from
plasma might carry the potential of becoming a novel diagnostic
tool for any stage of schistosomiasis. With increased automation
and better instrumentation for molecular diagnostics, the cost
efficiency and quality of results in clinical laboratories can exceed
that of repetitive diagnostic determinations by microscopy. The
cost of reagents and consumables for our method range around 3
USD per determination, which is probably too expensive in many
endemic countries. However, this price is compatible with
Table 3. Patients seen after treatment.
Patient Country of origin Residence status Schistosoma species
a Histology
b YPE
c NT
d TPT
e Cell-free DNA cop/mL
f
1 Egypt Immigrant S. haematobium Negative 3 1 2 wk 6653.16
2 Sierra Leone Refugee Unclassified Negative 6 1 2 wk 89.92
3 Guinea Immigrant S. mansoni DE 8 1 4 wk 89.92
4 Sierra Leone Refugee Unclassified Negative 7 2 13 wk 43.88
5 Zimbabwe/Botswana Immigrant Unclassified Negative 4 1 2 wk 21.41
6 German Tourist Unclassified Negative 3 3 24 wk 10.45
7 Ghana Immigrant S. mansoni EO 2 4 54 wk 10.45
8 Data not available Immigrant Unclassified DE 2 2 58 wk 2.49
9 Germany Expatriate Unclassified DE 3 2 9 wk 2.49
10 Egypt Immigrant Unclassified Negative 4 5 52 wk 2.49
11 Cameroon Immigrant S. haematobium Negative 2 3 2 y -
12 Uganda Immigrant Unclassified Negative 3 1 0 y -
13 Germany Tourist S. haematobium Negative 3 3 1 y -
14 Germany Tourist S. mansoni Negative 3 3 2 y -
15 Philippines Immigrant S. japonicum DE 4 6 2 y -
16 Ghana Immigrant Unclassified EO 4 2 3 y -
17 Germany Tourist S. mansoni Negative 4 3 3 y -
18 Egypt Immigrant S. mansoni EO 5 1 0 y -
19 Egypt Immigrant Unclassified Negative 5 4 3 y -
20 Cameroon Immigrant Unclassified EO 6 2 5 y -
21 Egypt Immigrant S. mansoni Negative 6 4 4 y -
22 Ghana Immigrant S. haematobium DE/EO 10 1 0 y -
23 Germany Tourist Unclassified Negative 10 3 8 y -
24 Egypt Immigrant S. haematobium Negative 6 2 6 y -
25 Germany Expatriate Unclassified Negative 5 3 4 y -
26 Cameroon Immigrant Data not available Negative 5 3 4 y -
27 Germany Tourist Unclassified Negative 5 3 4 y -
28 Cameroon Immigrant Unclassified Negative 6 3 5 y -
29 Egypt Immigrant Unclassified Negative 7 4 4 y -
30 Data not available Immigrant Unclassified DE 8 2 8 y -
aIdentified by microscopy during earlier active disease episode (recorded data).
bMicroscopic findings in colon or bladder biopsy upon re-visit. DE=degenerated eggs; EO=eosinophilic infiltrates; Negative=normal histology.
cYears post exposure=time (years) between last exposure in endemic country and PCR testing.
dNumber of earlier treatment courses since last exposure.
eTime post treatment=time (wk=weeks; y=years) between completion of last treatment course and PCR testing.
fNote that 10 mL plasma were processed. 1 copy per PCR mL=1.67 copies per PCR vial.
doi:10.1371/journal.pntd.0000422.t003
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should be affordable for individualized application in emerging
countries. Instrumentation and expertise for proper PCR diag-
nostics has considerably improved in many countries due to the
demands created by HIV and TBC treatment programmes. If
future studies can prove the clinical benefits suggested here,
Schistosoma CFPD PCR may become a new priority in molecular
diagnostics in developing and emerging countries.
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